Institution Directory

Clinical trials at UT Southwestern Medical Center

Sites in Dallas, TX

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1264

Shown on this page

Current sort

Live official records

Conditions: Renal Cancer, Tumor, Solid, Kidney Cancer, Tumor, Tumor, Benign
Interventions: HistoSonics Edison System; Device
Lead sponsor: HistoSonics, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 15
States / cities: Los Angeles, California • Mission Viejo, California • New Haven, Connecticut + 10 more

Conditions: Glioblastoma, GBM
Interventions: Acetadote; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: E-CBSST, E-SC; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 60 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: San Diego, California • Dallas, Texas

Conditions: Depression, Mental Disorder in Adolescence
Interventions: Competent Adulthood Transition with Cognitive-Behavioral, Humanistic and Interpersonal Training; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 13 Years to 18 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Chicago, Illinois • Glenview, Illinois • Park Ridge, Illinois + 1 more

Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
Interventions: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 42
States / cities: Gilbert, Arizona • Phoenix, Arizona • Springdale, Arkansas + 31 more

Conditions: Leiomyosarcoma
Interventions: Lurbinectedin, Doxorubicin; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 24
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 18 more

Conditions: Chronic Kidney Disease
Interventions: L-Arginine, Placebo; Drug · Other
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 35 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Newark, Delaware • Dallas, Texas

Conditions: Coagulation Disorder
Interventions: TAK-330, SOC 4F-PCC; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 13
States / cities: Arkansas City, Arkansas • Sacramento, California • Englewood, Colorado + 10 more

Conditions: HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions: PLD Chemotherapy, CDX-1140, CDX-301; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 7
States / cities: Chicago, Illinois • Baltimore, Maryland • Chapel Hill, North Carolina + 3 more

Conditions: Hyper Bilirubinemia, Premature Infant
Interventions: Phototherapy lights; Device
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 22 Weeks to 27 Weeks
Enrollment: 1,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more

Conditions: Advanced Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Larotrectinib Sulfate, Magnetic Resonance Imaging, Radionuclide Imaging, X-Ray Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 122
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 95 more

Conditions: Breast Cancer
Interventions: Letrozole, Abemaciclib; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Dallas, Texas

About this UT Southwestern Medical Center institution page

What this page lists: ClinicalTrials.gov records that list UT Southwestern Medical Center in Dallas, TX as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UT Southwestern Medical Center

Filter and sort this campus

Live official records

The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)

Imaging Acetadote Metabolism in Glioblastoma

Optimizing CBSST With Executive Function Training for Schizophrenia (R33)

The PATHway Study: Primary Care Based Depression Prevention in Adolescents

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Cycled Phototherapy

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

About this UT Southwestern Medical Center institution page